Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Mitesh J. Borad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2700-2658; OpenAlex author ID A5018257387; NIH RePORTER profile ID 9611687. Sources: ClinicalTrials.gov.

Their work

Papers
32 (first author 0, last author 4)
Trials
3 (principal investigator on 3)
Grants
2
Labs led
2
Collaborators
125
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: 1 trial · 2011: 1 paper, 1 trial · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 4 papers · 2018: none · 2019: none · 2020: 3 papers · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: 4 papers, 1 grant · 2025: 2 papers · 2026: 7 papers, 1 grant

Papers 32

  1. Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma With Persistent Lymphovascular Invasio… Co-author DOI 10.1002/jso.70414↗
  2. Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. Co-author DOI 10.1038/s41598-026-40757-3↗
  3. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  4. KRAS in pancreatic cancer: from molecular biology to transformative therapeutics. Co-author DOI 10.1186/s13045-026-01863-x↗
  5. Integrative Proteomic Analysis Reveals VMG Oncolytic Virus–Induced Molecular Reprogramming in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-9943137/v1↗
  6. Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm. Co-author DOI 10.2147/dddt.s559325↗
  7. Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. Co-author DOI 10.3390/cells15060531↗
  8. Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.omton.2025.200937↗
  9. Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. Co-author DOI 10.21037/jgo-2025-100↗
  10. Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1007/s11523-024-01088-3↗
  11. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer. Co-author DOI 10.1080/14656566.2024.2304125↗
  12. Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic cancer. Co-author DOI 10.21037/jgo-24-157↗
  13. Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. Co-author DOI 10.2147/ceg.s390655↗
  14. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials. Co-author DOI 10.1016/j.esmoop.2022.100771↗
  15. Targeting leukemia inhibitory factor in pancreatic adenocarcinoma. Co-author DOI 10.1080/13543784.2023.2206558↗
  16. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
  17. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-p… Co-author DOI 10.1007/s10637-021-01164-9↗
  18. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/14656566.2022.2149322↗
  19. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13717↗
  20. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Co-author DOI 10.14309/ctg.0000000000000414↗
  21. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Co-author DOI 10.3389/fonc.2021.794009↗
  22. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.011↗
  23. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Co-author DOI 10.1016/j.pan.2020.06.015↗
  24. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  25. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1002/cncr.30927↗
  26. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Last author DOI 10.1097/cad.0000000000000437↗
  27. Immunotherapy in pancreatic cancer treatment: a new frontier. Last author DOI 10.1177/1756283x16667909↗
  28. 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Co-author DOI 10.1186/s40644-017-0125-5↗
  29. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1200/jco.2014.55.7504↗
  30. Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. Last author DOI 10.2217/fon.13.277↗
  31. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. Co-author DOI 10.1371/journal.pone.0043192↗
  32. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Co-author DOI 10.1200/jco.2011.36.5742↗

Trials 3

  1. Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients Principal investigator NCT01461915↗
  2. Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Ade… Principal investigator NCT01144455↗
  3. Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors Principal investigator NCT00743379↗

Grants 2

  1. New Therapuetics for Pancreatic Cancer R01CA265050↗
  2. HRD-IA signatures in pancreatic ductal adenocarcinoma UH3CA238926↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hani M. Babiker · 11 shared papers, 2017–2026 · strength 2.37
  2. Michael T. Barrett · 2 shared papers, 2 shared grants, 2012–2026 · strength 2.15
  3. Tanios Bekaii‐Saab · 11 shared papers, 2017–2026 · strength 1.92
  4. Pedro Luiz Serrano Usón · 7 shared papers, 2021–2026 · strength 1.27
  5. Umair Majeed · 6 shared papers, 2021–2026 · strength 1.23
  6. Mohamad Bassam Sonbol · 7 shared papers, 2017–2026 · strength 1.21
  7. Martín E. Fernández-Zapico · 2 shared papers, 1 shared grant, 2020–2026 · strength 1.16
  8. Himil J Mahadevia · 3 shared papers, 2024–2025 · strength 0.74
  9. Bolni Marius Nagalo · 3 shared papers, 2025–2026 · strength 0.70
  10. Omeed Moaven · 3 shared papers, 2025–2026 · strength 0.70
  11. Fernando Moura · 3 shared papers, 2023–2026 · strength 0.68
  12. Ahmed Elhariri · 3 shared papers, 2023–2025 · strength 0.63
  13. Daniel H. Ahn · 5 shared papers, 2017–2023 · strength 0.55
  14. Jing Wang · 2 shared papers, 2023–2024 · strength 0.50
  15. Nguyen H. Tran · 2 shared papers, 2024–2025 · strength 0.49
  16. Conner Daniel Hartupee · 2 shared papers, 2026 · strength 0.48
  17. Sudhakar Ammanamanchi · 2 shared papers, 2026 · strength 0.48
  18. Amirsalar Mansouri · 2 shared papers, 2026 · strength 0.48
  19. Jiří Adamec · 2 shared papers, 2026 · strength 0.48
  20. Douaa Albelal · 2 shared papers, 2024–2025 · strength 0.47
  21. Jason Scott Starr · 3 shared papers, 2021–2023 · strength 0.37
  22. Kabir Mody · 3 shared papers, 2021–2022 · strength 0.36
  23. Cody R. Eslinger · 1 shared paper, 2026 · strength 0.36
  24. Ben George · 1 shared paper, 2026 · strength 0.36
  25. Brian Matthew Wolpin · 2 shared papers, 2020–2026 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.